| Find Sources And More Here: NDRA Website. NDRA Presentation. -----
And as I mentioned above, (Nasdaq: NDRA) is on our radar based on 5 key potential catalysts Check them out:
#1. NDRA Potential Catalyst - With This Float Size, It Could Create The Potential For Heightened Volatility In A Blink.
According to info from the Yahoo Finance website, NDRA has a very low float.
In fact, the website reports this profile to have approximately 1.1Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
If the company provides more positive news towards the first part of 2026, could it help provide a breakout spark when paired with this volatility potential? -----
#2. NDRA Potential Catalyst - A Significant $30 Analyst Target Suggests Triple-Digit Potential Upside.
In December, Ascendiant Capital Markets' analyst Edward Woo released an update note on ENDRA Life Sciences Inc. (Nasdaq: NDRA) with a $30.00 price target.
From Wednesday's closing valuation, that target provides NDRA with a potential upside of over 600%!
Here are some highlights from the report:
Focused on TAEUS development: ENDRA has one main medical device candidate, the Thermo Acoustic Enhanced UltraSound (TAEUS) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT and MRI, but at a fraction of the cost and at the point-of-care.
Pivotal trial planned to start in early 2026: In August 2023, ENDRA filed its De Novo application with the FDA. The FDA’s target approval date is 150 days (~5 months or about January 2024). In May 2024, ENDRA announced that based on FDA feedback received, ENDRA will update its pivotal clinical study protocol and statistical plan for submission to the FDA as a next step. An FDA meeting is planned to confirm the endpoints and protocol, with the goal to launch ENDRA’s pivotal study by early 2026, and FDA submission by mid-2026.
Large market opp.: The company is launching its first TAEUS application to measure fat in the liver, which is used for early detection and monitoring of Steatotic Liver Disease (SLD) (aka Non-Alcoholic Fatty Liver Disease (NAFLD)). In 2011, over 1.4Bn people were affected by SLD/NAFLD/NASH around the world. Despite the increased incidence of SLD/NAFLD, there are no low-cost, accurate, and safe methods for measuring fat in the liver. TAEUS technology should enable to diagnose SLD earlier and monitor patients with related liver diseases more accurately and cost effectively than is possible with existing technology. -----
#3. NDRA Potential Catalyst - Key Data Results From A TAEUS® Feasibility Study Demonstrates Critical Findings.
ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use
Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring
ANN ARBOR, Mich., December 04, 2025--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or the "Company"), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS’ thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%.
These thresholds separate mild, moderate and severe disease, are widely used to make clinical therapy decisions in routine practice and are important for enrolling patients in clinical trials. The high accuracy of TAEUS at these specific points strengthens its potential as a practical, low-cost tool for the booming MASLD/MASH and obesity drug development landscape.
"Drug developers and payors need to know if a patient is above or below the specific thresholds that trigger costly therapies, reimbursement of those therapies or trial enrollment," said Alexander Tokman, CEO of ENDRA Life Sciences. "Our data show TAEUS tracks MRI-PDFF closely across the full SLD spectrum, including the critical 12-22% range. Additionally, at the 8% LFF threshold used for Rezdiffra™ reimbursement determination, TAEUS delivered a high PPV as well."
...
Read the full article here. -----
#4. NDRA Potential Catalyst - A Major Milestones Recap With New Strategic Initiatives Points To NDRA Being At An "Inflection Point."
ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results
ANN ARBOR, Mich., November 17, 2025--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (Nasdaq: NDRA) ("ENDRA" or the "Company"), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease ("MASLD") and metabolic dysfunction associated steatohepatitis ("MASH"), today provided a business update and reported financial results for the three and nine months ended September 30, 2025.
Business Update
Completed private placement of up to $14.4Mn. On October 23, 2025, the Company closed a private investment in public equity (PIPE) financing led by institutional in-vest-ors. The PIPE generated gross proceeds of approximately $4.9Mn before placement agent fees and expenses, with the potential for up to an additional $9.5Mn in future proceeds through warrant exercises.
Launched strategic initiative to enhance balance sheet flexibility. As previously announced by the Company on October 23 and November 13 of this year, ENDRA launched a strategic initiative designed to strengthen the Company’s long-term financial sustainability. As part of this initiative, ENDRA deployed a portion of its capital into an institutional grade reward-generating program supported by leading advisers and custodial partners. This program is structured to generate consistent, non-dilutive financial returns, while enhancing balance sheet flexibility and providing supplemental financial resources to support ENDRA’s operational and commercial objectives.
Regained Nasdaq compliance. With the completion of the October PIPE financing, the Company regained compliance with Nasdaq’s minimum st-ockholders’ equity requirement (Rule 5550(b)(1)), resolving the previously disclosed deficiency.
Completed single site clinical feasibility study of TAEUS® Liver. ENDRA confirms that it will soon release key results from its recently completed clinical feasibility study evaluating the performance of the 2025 redesigned TAEUS® device. The study assessed TAEUS®’s ability to measure liver fat content, a key biomarker for diagnosing and monitoring MASLD and MASH versus the industry’s gold standard, Magnetic Resonance Imaging (MRI-PDFF) test.
"We’re at a transformative inflection point," said Alexander Tokman, ENDRA’s Chief Executive Officer. "We have advanced on two critical fronts: financial sustainability for ENDRA and clinical validation for TAEUS®. The recent successful private placement along with our new treasury strategy have created a non-dilutive value engine that enhances our financial strength. By reducing costs and fortifying the balance sheet, we are laying the groundwork for efficient commercialization of our life-saving TAEUS® technology."
...
Read the full article here. -----
#5. NDRA Potential Catalyst - An Interesting Chart Positioning Could Put NDRA On Radar Watch.
Here was NDRA's 6-month chart at close on Wednesday.
As you can see above, NDRA closed above 3 key technical chart levels in its:
- 20-Day Simple Moving Average (SMA)
- 5-Day Exponential Moving Average (EMA)
- 13-Day EMA
With NDRA closing above those 3 levels Wednesday, could strong support be developing? -----
(Nasdaq: NDRA) Recap - 5 Explosive Potential Catalysts On Our Radar
#1. With This Float Size, It Could Create The Potential For Heightened Volatility In A Blink.
#2. A Significant $30 Analyst Target Suggests Triple-Digit Potential Upside.
#3. Key Data Results From A TAEUS® Feasibility Study Demonstrates Critical Findings.
#4. A Major Milestones Recap With New Strategic Initiatives Points To NDRA Being At An "Inflection Point."
#5. An Interesting Chart Positioning Could Put NDRA On Radar Watch. -----
Coverage is officially initiated on ENDRA Life Sciences Inc. (Nasdaq: NDRA).
Be on the lookout for updates heading your way shortly. Talk soon.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
Source (1) - The Lancet: “The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis” | July 2022
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 02/25/2026 and ending on 02/26/2026 to publicly disseminate information about (NDRA:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). These Funds were part of the twenty five thousand USD funds that TD Media LLC received from a third party named Awareness Consulting Network LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (NDRA:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/ndra-mvuft/#details | 
0 التعليقات:
إرسال تعليق